Table 3.
Clinicopathological features of HCC patients whose intrahepatic cccDNA levels were measured by ddPCR
| Patients (n = 30) | n (%) |
|---|---|
| Age (years) | |
| < 50 | 13 (43.33) |
| ≥ 50 | 17 (56.67) |
| Sex | |
| Male | 26 (86.67) |
| Female | 4 (13.33) |
| Serum HBsAg | |
| Positive | 18 (60.0) |
| Negative | 12 (40.0) |
| Serum AFP | |
| < 500 ng/ml | 19 (63.33) |
| ≥ 500 ng/ml | 8 (26.67) |
| Unknown | 3 (10.0) |
| Tumor size | |
| < 5 cm | 12 (40.0) |
| ≥ 5 cm | 18 (60.0) |
| TP53 expressions | |
| Negative | 16 (53.33) |
| Positive | 14 (46.67) |
| Ki-67 expression | |
| < 10% | 8 (26.67) |
| ≥ 10% | 22 (73.33) |
HBsAg hepatitis B surface antigen, AFP alpha-fetoprotein, HCC hepatocellular carcinoma, TP53 tumor suppressor protein p53